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Differential stromal reprogramming 
in benign and malignant naturally 
occurring canine mammary 
tumours identifies disease-
modulating stromal components
Parisa Amini1,5, Sina nassiri2,5, Alexandra Malbon3,4 & Enni Markkanen  1*
While cancer-associated stroma (CAS) in malignant tumours is well described, stromal changes 
in benign forms of naturally occurring tumours remain poorly characterized. Spontaneous canine 
mammary carcinomas (mCA) are viewed as excellent models of human mCA. We have recently reported 
highly conserved stromal reprogramming between canine and human mCA based on transcriptome 
analysis of laser-capture-microdissected FFPE specimen. To identify stromal changes between benign 
and malignant mammary tumours, we have analysed matched normal and adenoma-associated stroma 
(AAS) from 13 canine mammary adenomas and compared them to previous data from 15 canine mCA. 
Our analyses reveal distinct stromal reprogramming even in small benign tumours. While similarities 
between AAS and CAS exist, the stromal signature clearly distinguished adenomas from mCA. The 
distinction between AAS and CAS is further substantiated by differential enrichment in several hallmark 
signalling pathways as well as differential abundance in cellular composition. Finally, we identify 
COL11A1, VIT, CD74, HLA-DRA, STRA6, IGFBP4, PIGR, and TNIP1 as strongly discriminatory stromal 
genes between adenoma and mCA, and demonstrate their prognostic value for human breast cancer. 
Given the relevance of canine CAS as a model for the human disease, our approach identifies disease-
modulating stromal components with implications for both human and canine breast cancer.
It is well accepted that the microenvironment surrounding cancer cells, the so-called cancer-associated stroma 
(CAS), plays a central role in both cancer initiation as well as its progression1,2. CAS is composed of various 
non-cancer cells, among them fibroblasts, immune cells, vascular cells, as well as extracellular matrix. CAS affects 
tumour cells in several ways: directly by promoting growth and survival of tumour cells, and also by stimulating 
their invasive and migratory capacity, thereby promoting invasion and metastasis1,2. Thus, CAS is considered to 
be a major determinant of tumour malignancy. However, in contrast to malignant tumours, it remains largely 
unexplored whether and what stromal changes occur in benign forms of naturally occurring tumours, and how 
stromal changes in benign neoplasms compare to that of malignant tumours in the same tissue. Such knowledge 
has the potential to help identify disease-promoting and/or suppressive features of the stroma and identify novel 
prognostic and therapeutic targets therein.
Close resemblance with regards to both pathophysiology and clinical aspects have positioned spontaneously 
occurring tumours in the domestic dog as valuable model to enhance understanding of tumour biology in both 
canine and human patients3–5. In particular, canine simple mammary carcinoma (mCA) are regarded as excellent 
models for human mCA, as they recapitulate the biology of human mCA both histologically and molecularly, and 
overcome several of the limitations of rodent tumour models6–8. Canine simple mCA are malignant epithelial 
neoplasms that infiltrate the surrounding tissue, thereby inducing a strong stromal response, and can give rise to 
1Institute of Veterinary Pharmacology and Toxicology, Vetsuisse Faculty, University of Zürich, Zürich, Switzerland. 
2Bioinformatics Core Facility, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland. 3Institute of Veterinary 
Pathology, Vetsuisse Faculty, University of Zürich, Zürich, Switzerland. 4Present address: The Royal (Dick) School of 
Veterinary Studies and The Roslin Institute Easter Bush Campus, Midlothian, EH25 9RG, Scotland. 5These authors 
contributed equally: Parisa Amini and Sina Nassiri. *email: enni.markkanen@vetpharm.uzh.ch
open
2Scientific RepoRtS |         (2020) 10:5506  | https://doi.org/10.1038/s41598-020-62354-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
metastases9. In contrast, canine simple mammary adenomas are well-demarcated, non-infiltrative benign mam-
mary tumours generally associated with little fibrovascular supporting stroma9. Whether these benign adenomas 
can progress into more malignant forms, such as mCA, remains an unresolved controversy.
Given the central role of CAS in human cancer in general, and mCA in particular, it is likely to also play a 
key role in canine mammary tumours. To understand stromal reprogramming in canine mCA and how it com-
pares to human mCA, we have previously analysed CAS reprogramming in formalin-fixed paraffin embedded 
(FFPE) breast cancer tissue using by laser-capture-microdissection (LCM) and quantitative PCR (RT-qPCR), 
and further advanced the approach to analyse LCM subsections by next-generation sequencing (RNAseq)10,11. 
Using this powerful RNAseq-driven approach, we have very recently assessed stromal reprogramming in a set of 
15 canine mCA, and demonstrated strong molecular homology in stromal reprogramming between canine and 
human mCA, emphasizing the relevance of the canine model for the human disease also with regards to CAS 
reprogramming12.
For diagnostic and prognostic purposes, there is a high need for markers to reliably predict the clinical course 
of a tumour. This necessitates understanding what differentiates benign and malignant tumours on a molecular 
basis. Several studies have demonstrated differences between stromal expression patterns from human mCA in 
situ compared to invasive tumours, some of which can be used as predictive markers for disease13,14. However, 
data regarding stromal reprogramming in naturally occurring benign mammary tumours are inexistent. To ana-
lyse whether stromal reprogramming occurs in naturally occurring benign mammary tumours, and to compare 
stromal reprogramming between benign and malignant mammary tumours, we investigated 13 cases of canine 
mammary adenoma, and compared stromal reprogramming in canine adenoma to that in canine mCA12.
Results
Transcriptomic profiling of matched AAS and normal stroma from canine mammary adenomas 
isolated by laser-capture microdissection from FFPE specimens. To characterize stromal changes 
associated with canine simple adenomas, we isolated both adenoma-associated stroma (AAS) and matched nor-
mal stroma (i.e. stroma adjacent to unaltered mammary glands) from 13 FFPE samples of canine simple ade-
noma using our established protocol11,12. Of these, one pair had to be excluded due to extremely low sequencing 
depth (see methods for details). Patient characteristics for all adenoma cases that were included and representa-
tive images for tissue isolation can be found in Table 1 and Supplementary Figure 1. Pairwise sample-to-sample 
Pearson correlation analysis using all genes revealed a clear separation of normal stroma and AAS, demonstrating 
that AAS also undergoes a reprogramming that clearly differentiates it from normal stroma (Fig. 1a). Analysis of 
differentially expressed genes with a FDR cut-off of 0.05 and fold change threshold of 2 revealed 193 genes to be 
significantly deregulated in AAs compared to normal stroma, including 57 significantly up- and 136 significantly 
down-regulated genes (Fig. 1b and Supplementary Table 1). Over-representation analysis of GO terms associ-
ated with biological processes suggested changes in following GO categories: extracellular structure organisa-
tion, adhesion, response to organic substance and endogenous stimulus, regulation of multicellular organismal 
development, and responses related to the immune system (Fig. 1c). Moreover GO terms associated with cellular 
components revealed main changes pertaining to the extracellular matrix (Fig. 1d), which was also supported by 
GO terms associated with molecular functions, highlighting strong changes in binding of various ECM compo-
nents (Fig. 1e).
Validation of RNAseq data was achieved through RT-qPCR of 8 strongly up- and down-regulated genes 
(SCUBE2, MMP2, VIT, SDK1, STRA6, IGF2, PIGR, and SFRP1), all of which showed significant expression 
changes consistent with RNAseq (Fig. 2a–i). Up-regulation of α-smooth muscle actin (α-SMA) in AAS compared 
to normal stroma was further evident on protein level by immunofluorescence (IF), in line with RNAseq results 






1 f Rhodesian Ridgeback 8 yes 13
2 f Deutscher Wachtelhund 6 yes 20
3 f Golden Retriever 8 yes 24
4 f Cocker Spaniel 8 yes 22
5 f Coton de Tuléar 13 yes 29
6 f Epagneul Breton 8 yes 6
7 f Galgo Espanol 9 yes 7
8 f Pinscher 11 yes 15
9 f Basset 12 yes 9
10 f Chihuahua 9 yes 8
11 f Yorkshire Terrier 10 yes 11
12 f Mittelpudel 11 yes 4
13 f West Highland White Terrier 9 yes 4
Table 1. Overview of canine mammary simple adenoma cases included in this study. Clinical data from dogs 
with simple mammary adenoma; Case # = case number as referred to within this study; age = age at excision of 
tumour; age of sample = time between initial tumour excision and sampling of stroma/RNA extraction.
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(ACTA2 log2 fold-change 0.875, p-value 0.0015; Fig. 2k). As myoepithelial cells tend to stain strongly for a-SMA 
in both normal and neoplastic mammary tissue, it cannot be excluded that there are myoepithelial cells as well as 
activated fibroblasts within the neoplasm in this image that stain positively for α-SMA. However, the solid areas 
of positive cells between acini in a simple adenoma are more suggestive of stromal cells. Furthermore, consistent 
with sequencing results (VIM log2 fold-change -1.044, p-value 2.58 E-08; Fig. 2l), vimentin expression decreased 
from normal stroma to AAS. Taken together, our data clearly demonstrate the occurrence of extensive stromal 
reprogramming in these benign naturally occurring tumours that is mainly driven by changes in the extracellular 
matrix, fibroblast activation and components of the immune system.
The stromal signature distinguishes benign from malignant mammary tumours. To understand 
how stromal reprogramming in benign canine mammary adenomas compares to malignant mCA, we juxtaposed 
our AAS dataset to a dataset of matched CAS and normal stroma from 15 canine mCA that we had obtained 
using the same methodology as previously reported12. As the histopathological appearance of normal, unin-
volved stroma showed no difference between adenomas and mCA as expected, we merged the two data sets while 
adjusting for potential batch effects (see methods for details). Interestingly, PCA of the combined data showed 
three homogenous yet distinct clusters with the first two principal components clearly separating AAS and CAS 
from each other as well as from their normal counterparts, supporting the notion that stromal reprogramming 
is strongly influenced by the type of tumour (Fig. 3a). Furthermore, AAS seemed to be much more similar to 
normal stroma than CAS, suggesting that the stroma undergoes a gradual change during the development of 
malignant tumours.
Figure 1. RNAseq-based transcriptomic analysis of cancer-associated stroma and matched normal stroma 
from 13 canine simple mammary adenoma. (a) Pairwise Pearson correlation analysis of adenoma-associated 
stroma (AAS) and normal stroma samples isolated from canine simple adenoma. The analysis was performed 
using all genes. Normal = normal stroma, Tumor = AAS. (b) Scatter plot of fold change versus mean expression 
highlighting differentially expressed genes in tumour stroma compared to normal stroma, using FC > 2 and 
FDR < 0.05 as cut-off values. (c–e) Top 20 over-represented Gene Ontology (GO) terms associated with 
biological processes (c), cellular components (d), and molecular functions (e) among genes significantly de-
regulated in AAS compared to normal stroma.
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Complementary to differential expression and gene set enrichment analysis which focus on individual genes 
and previously annotated gene sets, weighted gene co-expression network analysis (WGCNA) is a systems 
approach that allows for unbiased screening of genes based on their interconnectedness, thus revealing the inher-
ent organization of the transcriptome that underlies the biology of interest and pointing out candidate targets and 
biomarkers for further investigation15,16. To start analysing transcriptional reprogramming of AAS and CAS, we 
applied WGCNA on a subset of highly variable genes, and identified six clusters of highly positively correlated 
genes, hereafter referred to as gene modules (Fig. 3b, Supplementary Figure 5, Supplementary Table 3). Closer 
inspection of module eigengenes as the summary of the expression pattern within each module revealed four 
potentially interesting modules whose expression significantly differed between normal stroma, AAS and CAS: 
modules blue, brown, turquoise and yellow (Fig. 3c). Module blue showed progressive down-regulation from 
normal to AAS to CAS, module turquoise showed opposite expression trends in AAS and CAS, whereas mod-
ules brown and yellow showed progressive overexpression from normal stroma to AAS to CAS. The observation 
that distinct modules were associated with AAS and CAS highlighted differential transcriptional reprograming 
between stroma in the proximity of adenomas and mCA. Finally, we examined intramodular connectivity to 
identify hub genes within each module of interest (Supplementary Table 3 for full list of genes). Figure 3d lists the 
top 5 genes with largest intramodular connectivity score serving as candidate hub genes for each module. The top 
5 genes of the blue module were CFHR4, CLEC3B, KLF4, SCARA5 and GALNT15; for the brown module, these 
were COL8A2, SORCS2, BGN, RUNX1, and IGFBP2; for the turquoise module, we identified SPINK5, DSG1, 
FLG2, KRT1, and DMKN; and for module yellow the top 5 candidates consisted of CDH1, ST14, EHF, KRT8, 
and KIAA1217. These findings reveal the inherent structure of the transcriptome underlying AAS and CAS, and 
Figure 2. Validation of selected genes from the adenoma data by IF and RT-qPCR. (a–h) Relative mRNA levels 
of AAS-associated genes in normal stroma and AAS isolated by laser-capture microdissection, measured by RT-
qPCR. (a): SCUBE2; (b): MMP2; (c): VIT; (d): SDK1; (e): STRA6; (f): IGF2; (g): PIGR; (h): SFRP1; Values are 
mean values ±SEM of four independent cases, normalized to expression levels in normal stroma (for SCUBE2, 
MMP2, VIT, and SDK1), or AAS (STRA6, IGF2, PIGR, and SFRP1), respectively. P-values were calculated using 
student’s t-test, and significance cutoff was set at p = 0.05. (i) Summary of the expression trends as detected by 
RT-qPCR and RNAseq. (k,l) Immunofluorescent staining of α-SMA (red) (k), or Vimentin (purple) (l) in AAS 
and normal stroma of a representative canine simple mammary adenoma. Dapi staining (blue) visualizes cell 
nuclei. The dashed white line indicates the border between AAS and normal stroma.
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its modular distinction between adenoma and mCA. The identified hub genes serve as potential biomarkers or 
candidate targets for pharmaceutical intervention and will be subject of future studies.
mCA differ in clinical and molecular aspects from adenomas. It is therefore reasonable to assume that dis-
tinct tumour-promoting pathways may be at play in the stroma from mCA compared to adenomas. Indeed, 
enrichment analysis of hallmark pathways among CAS from mCA, AAS from adenoma, and normal stroma 
revealed several hits that are significantly deregulated between normal stroma and stroma adjacent to adenoma 
and/or mCA. In both adenoma and mCA, interferon alpha response and angiogenesis were up-regulated, while 
UV response down and adipogenesis were down-regulated compared to normal stroma (Fig. 4a,b). In con-
trast, TGFbeta signalling, glycolysis, mitotic spindle, epithelial to mesenchymal transition, mTORC1 signalling, 
unfolded protein response, apical surface, interferon gamma response and G2M checkpoint showed significantly 
increased enrichment only in CAS (Fig. 4c), and pathways involving pancreas beta cells, fatty acid metabolism, 
spermatogenesis, heme metabolism and IL2-STAT5 signalling a significantly decreased enrichment only in CAS 
(Fig. 4d). Finally, significant up-regulation only in adenoma could be detected for androgen response and Myc 
targets V1, whereas decreased enrichment only in adenoma was detected for hypoxia. The full list of pathways 
and p-values can be found in Supplementary Table 4. Interestingly, for many of these pathways in AAS showed an 
intermediate enrichment between that of normal stroma and CAS, supporting the notion of progressive stromal 
adjustments to malignant transformation of the associated epithelium.
Given that AAS and CAS are composed of various different types of non-cancer cells, the observed differ-
ences may also be influenced by the presence of differential cellular infiltrates in the stroma adjacent to adenoma 
or mCA. To further assess the contribution of changes in cellular composition to the observed transcriptional 
reprograming of AAS versus CAS, we utilized a previously established algorithm to estimate the proportion of 
Figure 3. The stromal signature distinguishes benign from malignant canine mammary tumours. (a) Principal 
component analysis (PCA) of the batch-adjusted adenoma and mCA data combined. Defining each study as 
one batch, combined data was adjusted for potential batch effects under the assumption that normal stroma 
is similar between adenoma and mCA. Dark red = CAS from mCA, bright red = AAS from adenoma, dark 
blue = normal stroma from mCA cases, bright blue = normal stroma from adenoma cases. (b) Weighted 
gene coexpression network analysis reveals modules and hub genes associated with AAS and CAS. Modules of 
highly positively correlated genes withig the top 10% highly variable genes. (c) Association between module 
eigengenes and biological groups suggests four modules of interest: blue, brown, turquoise, and yellow. (d) List 
of top 5 hub genes from the selected modules and their intermodular connectivity values.
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main immune and stromal cells from CAS gene expression data17. Of the cell types quantified, cancer-associated 
fibroblasts (CAFs) and endothelial cells made up a large portion of the cellular composition of the stroma in all 
groups (Fig. 5a, Supplementary Figure 4). Of note, detection of CAFs in normal stroma most probably reflects 
the inherent difficulties in differentiating between fibroblasts and CAFs, and as such the CAFs detected by this 
Figure 4. Single sample gene-set enrichment analysis of hallmark pathways among normal stroma, AAS and 
CAS. Pathways with an ANOVA p-value smaller than 0.05 are shown. (a) Pathways up-regulated in both AAS 
and CAS compared to normal stroma. (b) Pathways down-regulated in both AAS and CAS compared to normal 
stroma. (c) Pathways up-regulated only in CAS compared to normal stroma. (d) Pathways down-regulated only 
in CAS compared to normal stroma. (e) Pathways up-regulated only in AAS compared to normal stroma. (f) 
Pathways down-regulated only in AAS compared to normal stroma.
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methodology can be interpreted as ‘fibroblast-like cells’ either in normal stroma or cancer stroma. We found the 
fraction of CAFs to be higher in CAS than AAS. In contrast, the relative abundance of endothelial cells was lower 
in CAS compared to AAS. These findings suggest that reprograming of AAS and CAS as manifested in deregu-
lation of genes and pathways is, at least in part, influenced by changes in the cellular composition of the stroma.
Analysis of most discriminatory expression features between AAS and CAS reveals genes with 
prognostic value for human breast cancer. To identify characteristic features and assess the contribu-
tion of individual genes to the observed differences between normal stroma, AAS and CAS, we next used Partial 
Least Squares Discriminant Analysis (PLSDA). Intuitively, PLSDA can be viewed as a supervised extension of 
PCA, in which principal components are rotated such that maximum separation is achieved between groups of 
observations. The loading vector of the PLS components can then be used to extract most discriminatory features. 
The expression profile of 40 most discriminatory genes as revealed by PLS loadings (Fig. 5b, Supplementary 
Figure 2 for selected genes, and Supplementary Table 2 for the full list of genes) revealed several interesting 
clusters of genes: i) genes that are strongly up-regulated in CAS from mCA, but remain practically unchanged in 
AAS compared to normal stroma (IGFBP2, POSTN, COL11A1, SFRP2, and others); ii) genes whose expression 
is similar between CAS and normal stroma, but strongly increases in AAS (such as CD74, STRA6, and PIGR); iii) 
genes that are strongly down-regulated in CAS (e.g. IGSF10, HMCN2, and CLEC3B); and iv) and genes that are 
strongly down-regulated specifically in AAS (e.g. ARVCF, LANCL1, ITGA11, etc).
As CAS is known to exert a strong modulatory role on tumour progression, we reasoned that genes which 
are strongly differentially regulated between AAS and CAS could have a prognostic value for patient survival. 
Given the lack of long-term survival data for the canine cases included in this study, and the relevance of CAS 
from canine mCA for human breast cancer, we aimed to analyse the association of the human orthologues of the 
identified genes with survival. For this, we assessed the breast cancer (BRCA) subset of the TCGA database using 
Figure 5. Most discriminatory features between AAS and CAS reveals genes with prognostic value for human 
breast cancer. (a) Pie charts summarising the average cellular composition of normal stroma, AAS and CAS as 
obtained from the EPIC algorithm. Pie area corresponds to average cellular fraction in the respective group. 
(b) Heatmap of 40 most discriminatory genes between AAS, CAS and normal stroma from both conditions, 
as revealed by PLSDA. Top 20 features with largest absolute loading were selected separately for the first and 
second components of the PLSDA model. Full list of PLSDA loadings can be found in Supplementary Table 2. 
(c–e) Kaplan-Meier plots of cumulative survival for the indicated genes to visualize survival differences between 
the upper and lower 50th percentile of patients with a follow-up of 120 months.
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the TIMER software18. Among the genes from cluster i) that are up-regulated in CAS, high (top 50%) COL11A1 
expression was found to be significantly associated with worse survival (Fig. 5c). In contrast, for the genes in 
cluster iii), which are decreased in CAS, high VIT expression was found to be significantly associated with better 
survival (Fig. 5d). Strikingly, for genes in cluster ii), which are specifically up-regulated in AAS, high expression 
of 7 of the top 10 genes (C3, CD74, HLA-DRA, STRA6, IGFBP4, PIGR, and TNIP1) was strongly associated with 
better cumulative survival than tumours with low expression of these genes (Fig. 5e). Of note, IGHM expression 
could not be assessed in the dataset. Given their differential expression in benign versus malignant tumours as 
well as their association with a prognostic value, these genes are potentially interesting targets and their mecha-
nistic relevance should be interrogated in future studies.
Taken together, our data demonstrate that the stromal signature clearly distinguishes benign adenomas from 
malignant canine mCA, suggesting that the stroma could be a discriminatory feature influencing the clinical 
course of the disease. Furthermore, our analyses specific perturbations of several candidate genes and signalling 
pathways as well as cell types to be associated with CAS of malignant tumours, and identify novel stromal targets 
associated with tumour malignancy and prognosis with relevance for human breast cancer.
Discussion
CAS plays a key role in cancer initiation and progression in human cancer1,2. For diagnostic and therapeutic pur-
poses, there is significant interest in understanding how stromal reactions between benign and malignant forms 
of the disease differ. This necessitates understanding what differentiates mCA from adenomas on a molecular 
basis. Stromal gene expression has indeed been shown to predict clinical outcome in invasive breast cancer19,20. 
Several studies have demonstrated differences between stromal expression patterns from human tumours in situ 
compared to those that display invasive properties, some of which can be used as predictive markers for disease 
(e.g.13,14,21). Similarly, studies using mouse models have analysed changes in stromal cell populations at different 
stages of mCA progression (e.g.19). To the best of our knowledge, however, there is no dataset (human or other) 
available that describes stromal reactions in naturally occurring benign mammary adenomas that could be used 
to compare to malignant mCA. Thus it remains unknown whether the stroma around benign adenomas under-
goes reprogramming, and if so, what changes occur at the molecular level. As a consequence of this, it is unclear 
how these changes in benign neoplasms compare to malignant tumours of the same tissue. Such knowledge has 
the potential to help identify both disease-promoting and/or suppressing stromal features and identify novel 
prognostic and therapeutic targets therein. Given that canine mammary tumours are regarded as valuable model 
for human breast cancer, and the central role of CAS in human cancer in mCA, we have recently analysed stro-
mal reprogramming in canine mCA, and demonstrated the presence of strong molecular homology in stromal 
reprogramming between canine and human mCA, emphasizing the relevance of the canine model for the human 
disease10–12. To understand whether stromal reprogramming also occurs in benign mammary tumours, and to 
compare stromal reprogramming between benign and malignant mammary tumours, we have now analysed 
stromal reprogramming in 13 cases of canine mammary adenoma and compared it to that in canine mCA.
Here we report that AAS from benign canine adenoma undergoes a reprogramming that clearly differentiates 
it from normal stroma, with major changes in GO terms related to extracellular structure organisation, adhe-
sion, response to organic substance and endogenous stimulus, regulation of multicellular organismal develop-
ment, immune responses, and the extracellular matrix (Fig. 1). These changes are consistent with fibroblast- and 
immune-cell driven remodelling of the tumour microenvironment, which are known to be heavily involved in 
tumour biology of mCA1,2. Indeed, we find clear signs of fibroblast activation and reprogramming, as evidenced 
by the increase in α-SMA and the decrease in vimentin by IF (Fig. 2), which is also seen in malignant canine 
mCA10,12,22. It is interesting that the stroma surrounding adenomas shows such a clear reprogramming, as these 
non-infiltrative benign mammary tumours are generally associated with little fibrovascular supporting stroma9. 
Of note, α-SMA reactive fibroblasts or slight up-regulation of several matrix-metalloproteinases and their inhibi-
tors have been detected in benign and malignant lesions of the human breast23–28, as well as the canine mammary 
gland22. Hence, this first detailed glimpse into AAS surrounding spontaneous benign tumours of the breast sug-
gests that stromal reprogramming is an early reaction to development of benign tumours and is characterized 
by strong transcriptional responses, the molecular minutiae of which have to be elucidated in future studies. The 
obvious stromal reprogramming adjacent to adenomas suggests a subset of alterations in the extracellular matrix 
to be early events in reactive stroma during initial tumour development, and not depend on tumour malignancy. 
Fibroblasts are the most abundant cells of the connective tissue, and responsible for production and mainte-
nance the extracellular matrix29. Due to a very strong innate plasticity of fibroblasts, these cells are highly reactive 
towards changes in their environment, which gives rise to their inherent heterogeneity with regards to both phe-
notype and function. This makes them ideally adapted to fulfil very diverse roles ranging from maintenance of 
physical tissue support, wound healing to modulating inflammatory processes and supporting tumour growth. It 
thus seems that these changes in extracellular matrix composition might be mainly driven by fibroblast activation. 
Of note, this activation does not necessarily equal an increase in numbers of fibroblasts present, but may simply 
reflect their transcriptional status. It is well accepted, that the composition of the extracellular matrix strongly 
changes during tumour progression2. Recent advances have revealed a multitude of specific subpopulations of 
cancer-associated fibroblasts that display strong phenotypic diversity and functional heterogeneity (e.g.29,30). It 
will be of great interest now to investigate the detailed changes that discriminate the ‘early fibroblastic reaction’ 
that might be indiscriminate towards hyperplasia within a given epithelium from the reaction associated with 
malignant tumours to understand how the fibroblastic response changes in relation to tumour cell malignancy, 
and vice versa.
While not completely resolved, there is clear evidence that canine mammary gland tumours are a continuum 
from benign to malignant, supporting the comparison of canine mammary adenomas and mCA as different states 
of malignancy of the same disease31. Interestingly, PCA of the combined AAS and CAS shows adenoma-derived 
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stroma to be much more similar to normal stroma than CAS from mCA, suggesting that the stroma undergoes 
a gradual change during the development of malignant tumors. This was further corroborated by WGCNA and 
enrichment analysis of hallmark pathways among CAS, AAS and normal stroma, where many of these pathways 
in AAS showed an intermediate enrichment between normal stroma and CAS (Figs. 3 and 4). With respect to the 
cellular composition, cancer-associated fibroblasts (CAFs) and endothelial cells made up a large portion of the 
cellular composition of all three groups (Fig. 5). We found the fraction of CAFs to be higher in CAS versus AAS, 
suggesting CAFs to be strong drivers towards tumour malignancy, consistent with current literature29. The rela-
tively high number of CAFs in the normal stroma likely reflects the difficulties in differentiating between normal 
fibroblasts and CAFs based on subtle differences in their gene expression profiles. The lower relative abundance of 
endothelial cells in CAS compared to AAS is in line with the observation that malignant tumours often harbour 
large hypoxic or even necrotic areas due to insufficient vascular supply in relation to their strong proliferative 
properties. Indeed, a hypoxic tumour microenvironment and tumour progression are strongly linked32. Thus, 
we find that the stromal reprograming as manifested in deregulation of genes and pathways is, at least in part, 
also influenced by changes in the cellular composition of the stroma. Future work exploiting the composition of 
CAS and AAS, e.g. using single cell methods to simultaneously characterise changes in composition and state at 
the single cell resolution between benign and malignant tumours would help elucidating such changes further.
Identification of the hub genes (Fig. 4) SPINK5, DSG1, FLG2, KRT1, and DMKN the turquoise module, which 
is strongly decreased in CAS compared AAS, is highly interesting, since all of these genes have been strongly 
linked to maintenance of epithelial differentiation and integrity33–37. This suggests an important function of stro-
mal reprogramming in destabilization of epithelial differentiation and integrity. For module yellow, which is 
progressively up-regulated from normal stroma to adenoma to mCA, the top candidate hub genes consisted of 
CDH1, ST14, EHF, KRT8, and KIAA1217, all of which have important roles in epithelial cells, and/or are asso-
ciated with tumour malignancy38–41. Similarly, hub genes of module brown, COL8A2, SORCS2, BGN, RUNX1, 
and IGFBP2, displayed a progressive increase from normal stroma to AAS to CAS. These genes have important 
functions in the extracellular matrix and cell differentiation, and some have been associated with tumor pro-
gression or bad outcome in breast cancer20,42–45. Collectively, these findings reveal differences in transcriptional 
reprogramming of the stroma between benign and malignant breast tumours, and identify hub genes that could 
serve as potential biomarkers or candidate targets for pharmaceutical intervention. The detailed elucidation of the 
impact of these candidates to disease progression shall be subject of future studies.
Finally, by comparing stromal reprogramming in benign canine mammary adenomas to malignant mCA, we 
identified a list of gene targets that clearly distinguish AAS of benign adenomas from CAS in malignant mCA, 
further supporting the notion that the stroma has the potential of being a discriminatory feature influencing the 
clinical course of the disease (Fig. 5). Importantly, some of these differentially expressed genes show prognos-
tic value for human breast cancer, demonstrating the value of comparative expression analyses across species. 
Interestingly, the gene cluster harbouring the most of these prognostic genes is overexpressed specifically in ade-
noma, arguing for a protective role for these genes against malignant progression. Given the involvement of many 
of these genes (such as C3, CD74, HLA-DR, STRA6, IGFBP4 and PIGR) in immune-mediated processes46–50, 
it is tempting to speculate that their up-regulation indicates immune-mediated tumour control that is lost in 
malignant tumours. Additionally, we found specific perturbations of e.g. EMT and glycolysis to be associated 
with CAS of malignant tumours (Fig. 4). EMT-related genes such as COL11A1, COL8A2, and ADAM12 that are 
overexpressed in mCA (Fig. 5) could thus be potential biomarkers for canine invasive mCA, similarly to human 
mCA51–53. In the glycolysis pathway, PLOD1/2, FUT8 and TSTA3 are deregulated genes that participate in metab-
olism and glycolytic processes, which can influence the malignant transformation of cells, tumour development 
and metastasis54–56. Further functional assessment of the differentially expressed targets and their association with 
tumour malignancy should be determined in future studies.
To conclude, we provide a first detailed view of stromal reprogramming in naturally occurring benign mam-
mary adenomas, which demonstrates the occurrence of strong stromal reprogramming even in small benign 
tumours. Furthermore the stromal signature clearly distinguishes benign adenomas from malignant mCA, allow-
ing identification of several hub genes as potential molecular drivers in the stroma. Given the relevance of canine 
CAS as a model for the human disease, our approach identifies potential stromal modulators of the disease with 
implications for human mCA.
Methods
Aim, case selection and tissue processing. We isolated AAS and matched normal stroma from FFPE 
tissue sections of canine mammary adenoma by LCM for transcriptome analysis by RNAseq. For this, 13 canine 
simple mammary adenoma samples were obtained from the Institute of Veterinary Pathology of the Vetsuisse 
Faculty Zürich (Table 1). All samples were archival formalin-fixed, paraffin-embedded tissue samples either from 
the Animal Hospital of Zurich or external referral cases from veterinarians practicing in Switzerland. Details 
regarding selection criteria are described in10. Paraffin blocks were routinely kept at room temperature. Tissue 
processing for LCM was performed as described in11. All cases were reviewed by a veterinary pathologist. Criteria 
for case selection included female dogs, simple mammary adenoma, and sufficient tumour stroma content for 
tissue isolation. Table 1 provides clinical details, such as age and breed of each patient, sample age and tumour 
type, for all cases included in the study.
Laser-capture microdissection. Laser capture microdissection (LCM) for selective isolation of matched 
AAS and normal stroma was performed as previously described10–12. Areas for dissection were reviewed by a vet-
erinary pathologist. Highly enriched populations of normal or tumour-associated stroma were identified and iso-
lated according to the manufacturer’s protocol. Normal stroma samples were isolated from the same slides, from 
regions specified by a pathologist that were adjacent to unaltered mammary glands and presented no obvious 
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alterations and were at least 2-4 mm away from the tumour, in accordance with established procedures20. Isolation 
of cells of interest was verified by microscopic examination of the LCM cap as well as the excised region after 
microdissection (Supplementary Figure 1).
RNA isolation. RNA was isolated using the Covaris truXTRAC FFPE RNA kit and the Covaris E220 focused 
ultrasonicator as described in11. Details about RNA concentration, yield, and quality for adenoma samples can be 
found in Supplementary Table 5.
Quantitative RT-PCR. Quantitative RT-PCR using Taqman primers was performed as described in11. 
Primers are detailed in Supplementary Table 6.
Immunofluoresence. Immunofluorescence was performed as outlined in12. Antibodies and conditions used 
for immunofluorescence are detailed in Supplementary Table 7.
RNA sequencing library preparation. 10 ng of RNA from Elution 1 (E1) diluted to a concentration of 
0.33 ng/μl in a total volume of 30 μl was submitted for next-generation RNA sequencing and analysed as outlined in12.
Bioinformatics analyses. RNAseq quantification was performed with kallisto 0.44.0 with sequence-based 
bias correction using transcript sequences obtained from ENSEMBLE (CanFam3.1)57. Kallisto’s transcript-level 
estimates were further summarized at the gene-level using tximport 1.8.0 from Bioconductor58. Both raw data 
and gene-by-sample matrix of estimated counts have been deposited online and are publicly accessible from Gene 
Expression Omnibus (GEO) under accession number GSE135454. One of the normal stroma samples (14_nor-
mal) had extremely low sequencing depth and therefore was excluded along with its AAS pair (14_tumor) from 
downstream analyses. Carcinoma data was processed similarly as previously reported12, and can be accessed from 
GEO under GSE135183.
Prior to downstream analyses, lowly abundant genes were filtered out, and except for differential expres-
sion analysis, mean-variance trend was adjusted for using the variance-stabilizing transformation from DESeq. 2 
1.22.0 package59. Pairwise sample Pearson correlation was computed in the adenoma data with top 10% most var-
iable genes, and visualized using the pheatmap R Package60, with clustering distance and method set to Euclidean 
and ward.D2, respectively. Differentially expressed genes were identified using DESeq2 1.22.059, with FDR = 0.05 
and FoldChange=2 as significance thresholds. Over-representation analysis of Gene Ontology terms among sig-
nificant genes was performed using the MSigDB webtool (http://software.broadinstitute.org/gsea).
For comparisons involving adenoma and carcinoma samples, the two datasets were merged using an inter-
section of genes present in both, followed by removal of lowly abundant genes. Treating each study as one batch 
and under the assumption that normal stroma is similar between adenoma and mCA, merged expression data 
was adjusted for potential batch effects using the ComBat empirical Bayes framework as implemented in the SVA 
3.30.1 from Bioconductor61. To further mitigate technical noise, batch-corrected expression data was further 
adjusted for global differences across samples using quantile normalization as implemented in the limma 3.38.3 
package from Bioconductor62. PLSDA was implemented using mixOmics 6.6.2 from Bioconductor63, with the 
number of components included in the model set to 2. Single-sample gene set enrichment analysis was performed 
using the ssGSEA functionality within GSVA 1.30.0 from Bioconductor64. In silico enumeration of cell types from 
bulk tissue gene expression data was performed using the EPIC algorithm17.
Coexpression network analysis was performed using WGCNA R package65. In brief, pairwise similarities were 
computed between top 10% most variable genes using biweight midcorrelation, and converted to an adjacency 
matrix with soft thresholding power set to 8. A signed topological dissimilarity matrix was then computed based 
on the adjacency matrix, and hierarchically clustered using the Ward’s minimum variance method. Following 
adaptive branch pruning of the clustering dendrogram, six gene modules were identified. To summarize the 
expression pattern within each module, module eigengene (defined as the 1st principal component) was com-
puted, and aligned along the average expression of the module to enhance interpretability. Finally, hub genes 
were identified based on the connectivity of nodes to other nodes within the same module, and visualized using 
Cytoscape66.
Ethics approval and consent to participate. No animals were killed for the purpose of this research pro-
ject, as the tissue analysed had been surgically removed in a curative setting with the verbal consent of the patient 
owners. According to the Swiss Animal Welfare Law Art. 3 c, Abs. 4 the preparation of tissues in the context of 
agricultural production, diagnostic or curative operations on the animal or for determining the health status of 
animal populations is not considered an animal experiment and, thus, does not require an animal experimen-
tation license. All the used FFPE specimen were obtained for diagnostic reasons and do therefore not require a 
formal ethics approval, in full compliance with national guidelines.
Data availability
Raw and processed sequencing data reported in this study have been deposited to Gene Expression Omnibus with 
the primary accession number GSE135454 and GSE135183. All other data supporting our findings is contained in 
the manuscript, in Supplementary Figures 1–5 and Supplementary Tables 1–7.
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